#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest https://t.co/Rj1k1z0Tsz

Window of opportunity for abatacept in RA-ILD. Early treated patients (<6 months vs >2 years) appear to do better in terms of FVC. Abstr#2173 #ACR23 @RheumNow https://t.co/14IsA1KbAk https://t.co/ZbZEwzaOu0

L20 @ #ACR23 New therapy on the horizon for RA pts that failed MTX? ⭐️Telitacicept = recombinant fusion protein targeting & neutralizing BLyS & APRIL ➡️ placebo-controlled, phase III trial, 24w 👉at wk 24, PBO pts switched to drug arm for 24 more wks ➡️ 479 pts w/… https://t.co/94MyC8sdaG https://t.co/x3MUmFJPK6

Will CAR T Cells also treat RA? Dr. Jonathan Kay reports on abstract 0424 from #ACR23. https://t.co/XvNMXAFkWe https://t.co/HVvBLhqe8H

• Will CAR T Cells also treat RA? | RheumNow

👨‍⚖️ The Great Debate: should we use advanced therapies / biologics at disease onset in PMR & GCA? #ACR23 By Dr. Robert Spiera & Dr. Phil Seo @philseo #Vasculitis #PMR #GCA https://t.co/rkcUeEBLeZ

Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY

Daily Recap - TUESDAY https://t.co/Vq5BSHmPsv

• Dr. John Cush

ARTIC REWIND RCT 3 yrs csDMARD withdrawal 38% 3yrs csDMARDs free remission vs. 80% stable dose gpe 75% recovery after restart Rx progression 19% in half dose gpe More use bioDMARDs (18%) & GCs (50%) withdraw gpe Trends towards lower infections @RheumNow #ACR23 #ACRBest https://t.co/jhOINV7LLS

#CAR T cells #ACR23 🔥Back to back Sessions on one of the most avidly researched area in Rheum! 💡Check out these slides to understand: ☣️Toxicities and Limitations of CAR T therapy 🆕 Novel CAR designs ⚡️CAR cell sources ❓Research Questions to ponder! #ACRambassador https://t.co/6sOn4rjqY3

Toxicities and limitations of CAR therapy: the other side of its incredibly exciting, boundless potential @Michel_Sadelain @MSKCancerCenter #ACR23 @RheumNow https://t.co/L1UIqqlOdC

Dr. Sadelain gives a tour-de-force CAR-T overview for the future. Questions around programming antigen sensitivity and the life span of therapy are just the tip of the iceberg. #ACR23 @RheumNow https://t.co/oLog0SiQoE

Tapering ABA vs. stable dose ABA in RA No diff in DAS28 remission at 2 years But… Only in patients receiving concomitant MTX Those tapering ABA mono also experience higher functional important Of note: not an RCT @RheumNow #ACR23 ABST2542 https://t.co/yycCDTnRiF

How does CAR-T work and how many do we have? Dr. Sadelain details the history, manufacturing, and 6 currently FDA-approved CAR-T products. #ACR23 @RheumNow https://t.co/a4jGfhT8EU